- Home
- BAK vs BEAM Comparison
BAK vs BEAM Comparison
Compare BAK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- BEAM
- Stock Information
- Founded
- BAK 1972
- BEAM 2017
- Country
- BAK Brazil
- BEAM United States
- Employees
- BAK N/A
- BEAM N/A
- Industry
- BAK Major Chemicals
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAK Industrials
- BEAM Health Care
- Exchange
- BAK Nasdaq
- BEAM Nasdaq
- Market Cap
- BAK 2.3B
- BEAM 1.9B
- IPO Year
- BAK N/A
- BEAM 2020
- Fundamental
- Price
- BAK $5.20
- BEAM $24.05
- Analyst Decision
- BAK Strong Buy
- BEAM Buy
- Analyst Count
- BAK 3
- BEAM 11
- Target Price
- BAK $9.75
- BEAM $45.90
- AVG Volume (30 Days)
- BAK 597.8K
- BEAM 1.3M
- Earning Date
- BAK 11-06-2024
- BEAM 11-05-2024
- Dividend Yield
- BAK N/A
- BEAM N/A
- EPS Growth
- BAK N/A
- BEAM N/A
- EPS
- BAK N/A
- BEAM N/A
- Revenue
- BAK $13,764,416,401.00
- BEAM $349,643,000.00
- Revenue This Year
- BAK $14.26
- BEAM N/A
- Revenue Next Year
- BAK $8.26
- BEAM $6.04
- P/E Ratio
- BAK N/A
- BEAM N/A
- Revenue Growth
- BAK 2.86
- BEAM 328.73
- 52 Week Low
- BAK $5.12
- BEAM $20.84
- 52 Week High
- BAK $10.98
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- BAK 23.99
- BEAM 46.67
- Support Level
- BAK $5.83
- BEAM $21.46
- Resistance Level
- BAK $5.34
- BEAM $32.29
- Average True Range (ATR)
- BAK 0.20
- BEAM 2.04
- MACD
- BAK -0.07
- BEAM 0.19
- Stochastic Oscillator
- BAK 6.36
- BEAM 23.92
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.